Intuitive Surgical Inc (ISRG) - Forward Price-to-Revenue Multiple
Intuitive Surgical generates revenue through the sale of da Vinci systems and ancillary services. The forward price-to-sales ratio on the GURU.Markets daily chart shows that the value is holding at 9.00. Gary Guthart's strategy ensures niche dominance through R&D, while the increasing number of procedures creates powerful leverage to boost profits from consumables.
Intuitive Corp - analytical breakdowns and key metrics (ISRG)
- market price and analyst price targets:
- market capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Debt to Equity Intuitive Surgical|ISRG - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Intuitive Surgical|ISRG - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio Intuitive Corp|ISRG - Long-Term Debt Volume|Company Short-Term Debts Intuitive Surgical|Quick Liquidity intuitive.com
- business earnings and investment ratios data:
ISRG - Company Profit|Future Profit Intuitive Surgical|ISRG - Market Price to Net Income Ratio|Projected Price to Earnings Intuitive Surgical Inc|ISRG - PEG Multiple|EV/EBITDA Multiple Intuitive Corp|ISRG - Operating income before deduction of amortization|Net earnings per share for the last 12 months Intuitive Surgical|ISRG - Earnings per share for the last four quarters|Quarterly EPS earnings growth intuitive.com|ISRG - Expected net earnings per share growth this year|Expected earnings per share growth for next year Intuitive Surgical
- sales and revenue data:
General company analysis:ISRG (Intuitive)
To assess the credit quality of Intuitive Surgical (ISRG), the analyst compares market value with expected revenue. Stable demand for robotic surgeries minimizes revenue volatility, making the future P/S ratio a reliable indicator of overbought conditions. An increase in this metric signals inflated market expectations, whereas its decline amid a stable business opens a window for a fundamentally justified entry.
Analysis of competing companies
Price-to-Projected Revenue Ratio Danaher DHR|Forward Price to Sales BDX|STE: Forward Price-to-Revenue Multiple|WST - Forward P/S Multiple|Baxter International (BAX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple masimo.com|STVN (Stevanato Group) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Teleflex Inc. TFX|Price-to-Projected Revenue Ratio Merit Medical Systems Inc (MMSI)|Nobel Biocare - Market Cap to Projected Revenue|ICU Medical, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio XRAY (dentsplysirona.com)|LMAT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio AtriCure Inc ATRC|STAA: Forward P/S Multiple|NAGE - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio ZimVie Inc.|Market Cap to Projected Revenue ANGO (angiodynamics.com)|Forward Price-to-Revenue Multiple CERS (Cerus)|Price to Expected Revenue Ratio TKNO|Monogram Technologies Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Sharps Technology Inc STSS|InfuSystem Inc - Forward P/S Multiple|Market Cap to Expected Sales Ratio utahmed.com UTMD|KRMD (korumedical.com) - Forward Price-to-Revenue Multiple|NYXH: Price to Expected Revenue Ratio|MBOT (Microbot Medical Inc) - Forward P/S Multiple|Pro-Dex Inc. (PDEX) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple ZTEK (Zentek Ltd.)|Price-to-Projected Revenue Ratio ELUT (elutia.com)|Forward P/S Multiple MLSS (Milestone Scientific Inc.)|NEXGEL Inc. (NXGL) - Market Cap to Future Revenue Ratio|RVP: Forward Price-to-Revenue Multiple|Forward Price to Sales HBIO (harvardbioscience.com)|Femasys Inc. (FEMY) - Price-to-Projected Revenue Ratio|MHUA - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple POAI|Forward P/S Multiple Callan JMB Corp|Price-to-Projected Revenue Ratio Atrion Corp (ATRI)|NURO (NeuroMetrix Corporation) - Forward Price to Sales
